Tag Archives: vrx

Allergan Lifts Guidance; Valeant Suggests Higher Bid

Specialty drugmaker Allergan (AGN) reported solid Q3 results and raised its guidance Monday, as hostile suitor Valeant Pharmaceuticals International (VRX) said that it might raise its bid for the company again. Allergan’s Q3 earnings rose 45% over the year-earlier quarter to $1.78 a share, excluding one-time items. The result was at the high end of the guidance of $1.76 to $1.78 that Allergan gave on Oct. 9, though analysts’ consensus was still

Salix, Actavis Among Big Cap Pharmas In Merger Mambo

A one-on-one tango has since turned into a full-on hoedown as several major pharmaceutical companies continue to change partners on the M&A floor, with Valeant Pharmaceuticals (VRX) and Pershing Square Capital Management reportedly upping their bid Tuesday for Allergan (AGN) by $15 per share, according to the Wall Street Journal. The new bid would raise Valeant’s bid to about 191 a share. Allergan rose 2% in late trading to 190.20, extending

Valeant: Glaucoma Drug Is Potential Blockbuster

The Bausch & Lomb division of Valeant Pharmaceuticals International (VRX) announced positive late-stage trial results of a new glaucoma drug Thursday and projected it could sell more than $1 billion a year. Valeant popped over 6% in morning trading in the stock market today, though by early afternoon it was up just over 3%. Bausch & Lomb licensed the drug, Vesneo, from French biotech Nicox before it was acquired by Valeant last year. The two phase